Which Is Better for Treatment-Resistant Depression: TMS, ECT, or Ketamine?

October 24, 2026 · 6 min read

TMS, ECT, and ketamine-based care are not interchangeable choices after depression has resisted standard treatment: TMS is a noninvasive office treatment, ECT is the established option when severity or urgency dominates, and FDA-approved esketamine requires supervised monitoring. The best fit depends on symptom urgency, medical history, practical capacity, prior treatment, and a psychiatrist's assessment.

The useful question is not which option wins in the abstract. It is which trade-off fits the situation in front of you: speed, intensity, transportation, recovery time, side effects, insurance rules, and the kind of follow-up your life can realistically support. That distinction matters.

What counts as treatment-resistant depression?

Treatment-resistant depression commonly means depression that has not adequately responded to multiple antidepressant trials that were appropriate and taken as intended. The World Psychiatry review notes that the FDA and European Medicines Agency use a definition based on inadequate response after adequate treatment trials and adherence, while also cautioning that there is no single universal definition.

That caution is not a technicality. Before labeling depression resistant, a clinician may review whether a medication was used for an adequate duration and at an adequate dose, whether it could be tolerated, whether it was taken consistently, and whether evidence-based psychotherapy had a meaningful opportunity to help. Apparent resistance can sometimes be incomplete treatment exposure. A careful reset can save time.

When standard approaches truly have not helped, the same review identifies rTMS, ECT, intravenous ketamine, and intranasal esketamine used with an antidepressant as evidence-supported options. That does not make them a menu to self-select from. It makes a more focused psychiatric conversation possible.

How do TMS, ECT, and ketamine differ in how they are delivered?

They differ most visibly in setting and recovery burden: TMS is delivered while you are awake in an office, ECT is performed with anesthesia, and Spravato is administered under direct clinical supervision with required observation. The logistics are part of the treatment, not an afterthought.

Option	How it is delivered	Practical implication
rTMS	Magnetic stimulation in an office or clinic, without anesthesia	Repeated outpatient visits; the CMS policy describes no post-treatment limits on driving or working
ECT	A procedure using a short-acting general anesthetic and an intravenous muscle relaxant	Requires arranging around anesthesia and recovery; transportation planning is a sensible topic to raise with the treatment team
Spravato (esketamine)	FDA-labeled nasal spray administered under provider supervision in a restricted REMS program	Requires respiratory monitoring, including pulse oximetry, after every session and no driving until the next day after restful sleep
Racemic ketamine	Used off-label for depression	It is not the same FDA-labeled product or treatment pathway as Spravato

According to the National Institute of Mental Health, rTMS is FDA-cleared for treatment-resistant depression and is delivered without anesthesia. The CMS Local Coverage Determination describes it as weekday outpatient care and says there are no restrictions on driving, working, or operating machinery afterward. That can matter greatly when keeping a job, caregiving, or maintaining a household.

ECT carries a different bargain. NIMH describes common effects including headache, nausea, muscle aches, confusion, and memory loss. The treatment's established role in severe illness may outweigh those burdens for some people, but the decision needs room for the real-world details: time away from obligations, a support person when needed, and the experience of recovery.

Spravato deserves precise language. The DailyMed prescribing information identifies it as FDA-labeled esketamine for adults with treatment-resistant depression, either alone or with an oral antidepressant. Racemic ketamine is commonly used off-label for depression, which is why asking exactly which medication, setting, monitoring protocol, and follow-up plan a clinic offers is a practical safeguard.

For the rest of your support system, simple routines still have value even when treatment becomes more specialized. Planning a low-pressure reset, such as ideas in How Do I Plan a Restorative 48-Hour Getaway Near Home?, is not a substitute for treatment, but it can be one small way to protect recovery time.

Which treatment works fastest for severe depression?

ECT is the option most clearly associated with rapid response when depression is severe or life-threatening, while ketamine can also act rapidly and TMS is usually a more gradual outpatient course. Urgency changes the calculation.

NIMH says ECT is considered for severe treatment-resistant depression and when rapid response is needed in life-threatening circumstances, including catatonia, suicidality, or malnourishment. It also states that ECT generally begins working within the first week, faster than antidepressant medication. For an acute safety concern, the relevant next step is urgent clinical or emergency support, not comparing treatment options alone.

The evidence does not support a universal ECT-versus-ketamine winner. A 2025 clinical review in Focus describes ECT as the longstanding gold-standard intervention for severe treatment-resistant depression and ketamine as a rapid-acting alternative with patient-specific trade-offs. In the 2025 review, one hospitalized trial reported higher remission with ECT, while another trial in mainly outpatient adults with nonpsychotic treatment-resistant depression found ketamine noninferior on its response outcome. Different populations and protocols produced different answers. Context decides.

NIMH also notes that standard rTMS does not match ECT's therapeutic effects, although accelerated protocols may complete a course within a shorter timeframe. Faster scheduling is not automatically the same as the fastest clinical response. Ask a clinician to separate those two ideas clearly.

Frequently Asked Questions

What side effects and practical commitments should I expect with TMS, ECT, or Spravato?

TMS is delivered in an office or clinic without anesthesia; the CMS coverage policy describes no restriction on driving or working afterward. ECT involves general anesthesia and can cause headache, nausea, muscle aches, confusion, and memory loss, according to NIMH. Spravato can cause sedation, dissociation, dizziness, nausea, increased blood pressure, vomiting, and headache, and its label requires monitored administration and no driving or hazardous activity until the next day after restful sleep.

Does insurance usually cover TMS, ECT, or esketamine?

Coverage is not universal and depends on the plan, medical-necessity rules, documentation, and authorization process. A CMS Local Coverage Determination describes circumstances in which outpatient rTMS may be covered, but it applies through a Medicare contractor rather than every insurer. Ask the treatment program and insurer which treatment-specific requirements, records, and approvals apply before arranging care.

Can I try these treatments if antidepressants and therapy have not helped?

Potentially. The World Psychiatry review identifies rTMS, ECT, intravenous ketamine, and intranasal esketamine used with an antidepressant as evidence-supported options for treatment-resistant depression. A clinician still needs to confirm that prior treatments were adequate and adhered to, and to weigh urgency, safety, diagnostic context, and access constraints.

A useful appointment agenda: ask what diagnosis and prior-treatment history support the recommendation, what response timeline is realistic, what transportation or work accommodations are needed, what side effects warrant a call, and what maintenance plan follows improvement. No option requires perfection from you. It requires an informed conversation and a plan you can actually carry.

Sources

Disclaimer: This article is for general information only and is not medical advice. It is not a substitute for diagnosis or treatment by a qualified healthcare professional. Always speak to your doctor before acting on anything you read here.

Written and reviewed by the Snap Flicks Editorial Team. Learn how we create content.